Asthma Medication or Doping?

  • Author: Lisa-Marie Rauschendorfer
  • Published: 04 February 2017
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Drug Testing and Analysis
thumbnail image: Asthma Medication or Doping?

Salmeterol is a drug used for the treatment of airway diseases such as asthma. It is a chiral compound and most often administered in a 50:50 racemic mixture via inhalation. Only the (R)-salmeterol enantiomer causes a pharmacological response, while the (S)-enantiomer is considered pharmacologically inert.


For athletes, there is a permitted maximum of salmeterol of 200 µg in 24 h because the compound enhances exercise performance. Unfortunately, there is no urine threshold, as the enantioselective urinary pharmacokinetics are unknown, making effective doping controls impossible.


Glenn Jacobson, University of Tasmania, Australia, and colleagues used ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for the enantioselective salmeterol analysis of urine samples following a single administration of therapeutic doses of salmeterol (50 µg and 200 µg, respectively).


The team found that salmeterol can be detected for up to 24 hours after inhalation following a single 50 µg dose. The results also show that salmeterol displays some enantioselectivity in urinary pharmacokinetics. According to the researchers, these findings are relevant for the introduction of a urine threshold limit for salmeterol on the list of prohibited substances.


 

Article Views: 930

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH